

**Mahajan, Vinay**

---

**From:** Communications, Novartis (Gen)  
**Sent:** Friday, December 15, 2017 11:34 AM  
**Subject:** Letter to associates from Joe Jimenez: Novartis Leadership Announcement - December 2017



## Novartis Leadership Announcement

December 15, 2017

Dear Colleagues,

I would like to inform you that **Bruno Strigini**, *CEO Novartis Oncology*, has informed me that he decided to retire from Novartis and the industry for personal reasons.

I'd like to thank Bruno for his contributions, especially for successfully navigating the business unit through the Gleevec® patent expiration and leading the integration of the GSK Oncology Product Portfolio acquired in 2015. Please join me in wishing Bruno the best for his future.

Bruno will step back from his ECN mandate by the end of the year and fully hand over in early 2018. The internal and external search process for a new CEO Novartis Oncology is underway and we will announce his succession in due time.

I would like to use this occasion to thank the Oncology team for the important work you do. You bring important new therapies to patients in need and have delivered solid business performance despite the Gleevec patent expiration. Our plans and aspirations for Oncology will not change.

I wish you and your families a happy, well-deserved holiday break.

Joe

For internal use only and not to be shown, distributed or disseminated outside of Novartis

